Claudio Marasca
Claudio Marasca is an expert in Dermatology at Ospedale Antonio Cardarelli (Italy). As of October 2026, ScienceLeadR ranks Claudio Marasca in the top 1% of experts worldwide for Skin Diseases, Infectious. Claudio Marasca has authored 141 publications, the most recent in 2026, and is an investigator in 5 clinical trials, 2 of them ongoing. SLR score: 501 (community average: 125). How the SLR is computed.
LeadR Profile
Dermatology
Subspecialties: Public Health - Infectiology - Surgery
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 2015 - 2023
Number : 141
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| From prediction to prevention: Are we ready to intercept PsA before it begins? PMID 42926338 — sexually transmitted diseases, skin diseases | J Eur Acad Dermatol Venereol | 2026 | 0 |
| Real-World Effectiveness and Safety of Bimekizumab for Moderate-to-Severe Hidradenitis Suppurativa: A Multicenter Retrospective Study from the Italian Landscape HS (IL-HS). PMID 42663860 — abscess, quality of life, safety, pain, retrospective studies, hidradenitis suppurativa, drug-related side effects and adverse reactions, hidradenitis, therapeutics | Dermatol Ther (Heidelb) | 2026 | 1 |
| Tildrakizumab in the Treatment of Complex and Severe Psoriasis: A Case Series. PMID 42652566 — comorbidity, cardiovascular diseases, obesity, therapeutics, psoriasis, metabolic syndrome | J Clin Med | 2026 | 0 |
| Real-Life Effectiveness and Safety of Lebrikizumab in Elderly Patients with Atopic Dermatitis: A Multicenter Study. PMID 42423183 — safety, dermatitis, aged, dermatology, dermatitis, atopic | Clin Exp Dermatol | 2026 | 0 |
| Hidradenitis suppurativa: A paradigm of multidimensional burden and stigmatization. PMID 42132194 — sexually transmitted diseases, hidradenitis suppurativa, skin diseases, hidradenitis, therapeutics | J Eur Acad Dermatol Venereol | 2026 | 0 |
Clinical Studies 5
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Main Topics
Ongoing Clinical Trials
2 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| A Clinical Study in which patients with acne vulgaris will receive a new topical drug for long term The safety and efficacy of the drug will be tested 2023-510342-24-00 — safety, pharmaceutical preparations, acne vulgaris | Phase 3 | Active not recruiting | 2024 |
| A Long term Safety and Efficacy Study of N Acetyl GED 0507 34 LEVO Gel 5 in Subjects With Acne Vulgaris (GEDACNE LT) NCT07389109 — skin, safety, pharmaceutical preparations, acne vulgaris, therapeutics | Phase 3 | Active not recruiting | 2024 |
LeadR Networks
Main global connection map